Home › World Health Organization to Review Mercks Investigational Ebola Vaccine for Emergency Use Assessment and Listing
 

Keywords :   


World Health Organization to Review Mercks Investigational Ebola Vaccine for Emergency Use Assessment and Listing

2015-12-23 14:30:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the application for Emergency Use Assessment and Listing (EUAL) for the companys investigational Ebola Zaire vaccine, V920 (rVSVG-ZEBOV-GP, live attenuated), has been accepted for review by the World Health Organization (WHO). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Skip Irvine, 215-652-6059orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: world health review listing

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.05Atlantic Tropical Weather Outlook
28.05Low Environmental Impact Recycled Paints Arrive in Indonesia
28.05Eastern North Pacific Tropical Weather Outlook
28.05Ousted WeWork boss drops effort to return
28.05Baldwin Technology unveils new products at drupa
28.05Royal Mail owners to back 5bn takeover offer
28.05Malaysian printers turns to Vetaphone and Nordmeccanica
28.05Katun DPS promotes digital label printing at drupa
More »